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Abstract: Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-positive (Ph+) myeloid
cells. Ph+ cells occur via a reciprocal translocation between the long arms of chromosomes 9 and 22 resulting in constitutively active
Bcr-abl fusion protein. Tyrosine kinase inhibitors (TKIs) are used against the kinase activity of Bcr-abl fusion protein for the effective
treatment of CML. However, the development of drug resistance, directed by different genetic mechanisms, is the major problem
of clinical applications of TKIs. These mechanisms include mutations in the TKI binding site of Bcr-abl, overexpression of Bcr-abl,
overexpression of ATP binding cassette transporters, aberrant ceramide metabolism, inhibition of apoptosis, and changes in expression
levels of microRNAs. Recently, many studies have focused on understanding the molecular mechanisms of drug resistance in cancer
while targeting therapies providing reversal of resistance. Cancer stem cells also have roles in tumor initiation, maintenance, progression,
metastasis, and drug resistance. Uncovering the mechanisms of drug resistance can provide more efficient treatment of cancer since
these findings may provide novel targets for a complete cure. In this review, we discuss recent findings on the mechanisms of multidrug
resistance and its reversal in CML.
Key words: Chronic myeloid leukemia, drug resistance, tyrosine kinase inhibitor, Bcr-abl

1. Introduction
Chronic myeloid leukemia (CML) is a hematological
cancer characterized by the overproduction of mature or
immature myeloid cells in the peripheral blood, spleen, and
bone marrow. These cells are Philadelphia chromosome
(Ph)-positive in more than 90% of CML patients. The
Philadelphia chromosome results from a balanced
reciprocal translocation between the Abelson gene (Abl1)
on the long arm of chromosome 9 and the breakpoint
cluster region gene (Bcr) on the long arm of chromosome
22, t(9;22)(q34;q11). This balanced translocation results in
the Bcr-abl1 fusion gene, a constitutively active chimeric
tyrosine kinase (Al-Achkar et al., 2012; Calderón-Cabrera
et al., 2013; Press et al., 2013). Different sizes of the Bcrabl fusion protein are synthesized in different leukemias. A
Bcr-abl protein of 210 kDa is observed in more than 90%
of CML and 30%–35% of acute lymphocytic leukemia
(ALL) patients. Bcr-abl proteins of 190 and 230 kDa
are detected in ALL and chronic neutrophilic leukemia
patients, respectively (Chan at al., 1987; Deininger et al.,
2000; Kantarjian at al., 2006; Quintás-Cardama and Cortes,
2009). Bcr-abl tyrosine kinase activity causes malignant
cell transformation. The Bcr-abl oncoprotein affects some
downstream signaling pathways resulting in uncontrolled
* Correspondence: ybaran@gmail.com
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cell proliferation, decreased cell apoptosis, adhesion, and
differentiation. All these changes form the phenotypic
features of CML (Jagani et al., 2008). There are 3 phases
in CML, known as the chronic, accelerated, and blast
crisis phases. The transition from chronic to accelerated
phase and to blast crisis phase results from secondary
chromosomal aberrations such as trisomy 8, trisomy 19,
an extra Ph chromosome, and isochromosome 17q (p53
gene on 17p is lost) (Al-Achkar et al., 2012; Jabbour and
Lipton, 2013).
In the United States, the annual incidence of CML is
estimated at 1.0 to 1.3 per 100,000 or approximately 4800 to
5200 new cases annually. The estimated prevalence of CML
in the United States was approximately 25,000 to 30,000.
Therapy with imatinib has changed the demographics of
CML. The annual mortality was approximately 10% for the
first 2 years and 20% to 25% in the following years (Huang
et al., 2012).
Until radiotherapy was discovered in the 19th century,
arsenic was used for the treatment of CML. In the 1960s,
busulfan and hydroxyurea were used, while allogenic
stem cell transplantation has been used since the 1980s.
In the 1980s, patients not suitable for transplantation were
treated with interferon alpha, resulting in a survival rate
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of approximately 35% (Frazer et al., 2007). Understanding
the molecular mechanisms of CML resulted in the
development of tyrosine kinase inhibitors (TKIs) (Hamad
et al., 2013; Baccarani et al., 2014). Treatment with
TKIs increased survival rates, decreased side effects,
and improved life quality. As a result, the difficulties
encountered with previous therapeutic approaches have
been overcome (Nasr and Bazarbachi, 2012; Hamad et al.,
2013). The 2-phenylaminopyrimidines were first reported
as potent protein tyrosine kinase inhibitors with selectivity
for the Abl and platelet-derived growth factor receptor
(PDGF-R) tyrosine kinases (Buchdunger et al., 1995,
1996).
The first developed TKI was imatinib mesylate (Glivec
or Gleevec or STI571), which targets Bcr-abl protein. In
CML cells, the kinase domain of Bcr-abl is phosphorylated
at tyrosine residues and activated by ATP binding. Imatinib
mesylate mimics ATP and inhibits its binding to the
tyrosine kinase domain of Bcr-abl (Fausel, 2007). Different
studies demonstrated that patients with accelerated or
blast crisis phases can show resistance to imatinib (Gorre
et al., 2001; Sawyers et al., 2002).
In order to solve this problem, second-generation TKIs
were developed such as dasatinib (BMS-354825, Sprycel),
nilotinib (AMN 107, Tasigna), and bosutinib (SKI-606).
These agents showed better performance for the treatment
of CML as compared to imatinib (Hamad et al., 2013).
Nilotinib also binds to the ATP binding site of Bcr-abl and
inhibits the signaling cascade essential for the proliferation
of cells. The structure of nilotinib compared to imatinib is
more compatible in terms of the ATP binding pocket site
(Frazer et al., 2007). Unlike other TKIs, dasatinib binds to
both the active and inactive conformations of the Abl kinase
domain and targets some other kinases such as the Src
family, c-Kit, PDGF-R, and ephrin-A receptor. Dasatinib
is a prominent agent for imatinib-resistant CML patients
(An et al., 2010). Furthermore, the newly developed
second-generation drug bosutinib is used to treat solid
tumors by blocking Src-family kinase and Bcr-abl activity.
Unlike dasatinib, bosutinib does not target c-Kit and
PDGF-R, but rather causes phosphorylation of cellular
proteins and inhibits proliferation of CML cells (Weisberg
et al., 2007; Cortes et al., 2012). Lastly, ponatinib is a thirdgeneration drug specific for tyrosine kinase activity, which
particularly binds to Bcr-abl. In contrast to other drugs,
this treatment is efficacious against T315I-mutated CML
patients (~20% of imatinib-resistant patients).
Aurora kinases, which have a significant role in
mitosis, are overexpressed in cancer cells. Inhibition of
these kinases causes the mitotic catastrophe of leukemia
cells. Danusertib could be a substantial agent for new
therapies by inhibiting all aurora and Bcr-abl tyrosine
kinases (including T315I mutation) (Jabbour et al., 2013).

2. Drug resistance
Drug resistance is known as insensitivity of cancer cells
and tissues to anticancer agents. When a cell shows a drugresistance phenotype, it may also demonstrate resistance
to chemically and structurally different anticancer
agents. While clinical outcomes indicated the success
of tyrosine kinase inhibitors, development of resistance
in CML patients was reported as the major problem in
treatment of CML. There are different Bcr-abl dependent
and independent mechanisms contributing to multidrug
resistance in cancer. These mechanisms include mutations
in the TKI binding domain of Bcr-abl, overexpression
of Bcr-abl, ATP binding cassette (ABC) transporters,
aberrant ceramide metabolism, inhibition of apoptosis,
and changes in expression levels of certain microRNAs.
2.1. Bcr-abl mutations
Point mutations in the Bcr-abl kinase domain decrease
and/or inhibit the interaction of TKI and the oncogenic
Bcr-abl protein depending on the location of the mutation
(Figure 1). Alterations in critical contact points due to
amino acid substitutions increase the failure of agent
binding to the target site. In addition, drug treatment
can induce mutations leading to the development of
drug resistance and, thus, drug efficacy decreases during
treatment of CML. Point mutations are found more
frequently in advanced phase CML as compared to the
chronic phase of the disease. Mutations in the genome
can lead to dysfunction (An et al., 2010). It was shown
that 4 regions are essential for high frequency binding of
imatinib (P-loop, SH-3, SH-2, and A-loop). The P-loop is
responsible for phosphate binding and mutations in this
site were frequently observed in 43% of patients who were
generally in the acute and blast crisis phases. The P-loop
mutations Y253F and E255K increase the probability of
transformation depending on Bcr-abl kinase activity. The
most common mutation observed in imatinib-resistant
CML patients (T315I) has isoleucine instead of threonine
at the 315th amino acid in the Bcr-abl protein (Comert et
al., 2013; Figure 1). In our in vitro studies, we determined
that neither resistance to imatinib in K562 and Meg01 cells nor resistance to nilotinib in K562 cells resulted
from mutations in the TKI binding site of the Bcr-abl
oncoprotein (Baran et al., 2007a, 2007b; Camgoz et al.,
2013).
2.2. Overexpression of Bcr-abl
Overexpression of the Bcr-abl oncogene is another
mechanism of imatinib resistance. Bcr-abl transformed
murine hematopoietic cells and Bcr-abl positive human
cells were used to show amplification in the Abl gene
(An et al., 2010; Comert et al., 2013). In our studies, we
determined significant overexpression of Bcr-abl mRNA
and protein in imatinib-resistant K562 and Meg-01 cells
(Baran et al., 2007a, 2007b). On the other hand, a more
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Figure 1. Distribution of the mutations with respect to the main regions of the Bcr-abl kinase domain.

recent study revealed that there was also an important
increase in mRNA levels of Bcr-abl in nilotinib-resistant
K562 cells (Camgoz et al., 2013). More interestingly, our
group showed that there were also significant increases in
protein stability of Bcr-abl in imatinib resistant cells (Salas
et al., 2011).
2.3. ABC transporters
ABC transporters in the cell membrane are another
important mechanism of Bcr-abl independent drug
resistance (Eechoute et al., 2011). ABC transporters,
encoded by 49 genes, are a highly conserved
transmembrane protein family and import/export the
substrate by hydrolyzing ATP. Amino acids, sugars,
inorganic compounds, and hydrophobic substances
are imported/exported into or out of the cells by these
transporters. In addition, ABC transporters provide drug
efflux across organelles and the cell membrane (Vasiliou et
al., 2009). ABC transporters have 7 subfamilies, including
ABC-A, ABC-B, ABC-C, ABC-D, ABC-E, ABC-F, and
ABC-G. The ABC-B subfamily consists of 11 genes. The
first and best characterized ABC transporter is ABCB1
[known as the multidrug resistance (MDR1) transporter]
and it has a role in the multidrug resistance mechanism
(Juliano and Ling, 1976). It was reported that expression
levels of MDR1 are increased in imatinib-resistant K562
cells (Peng et al., 2012). Single nucleotide polymorphism
(SNP) analysis in the MDR1 gene could be effective to
predict imatinib efficacy in the treatment of CML patients.
A recent study demonstrated that genetic variations in
the MDR1 gene affect the drug transportation process.
The relationship between MDR1 polymorphism and
leukemia risk was determined according to alleles T and
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G at the SNP. The heterozygous genotype (GT) is related
to drug resistance of imatinib. However, it was determined
that recessive TT genotyped patients have developed a
mechanism against resistance to imatinib (Elghannam et
al., 2014). Changes in the expression levels of the MDR1
gene resulting in increased P-glycoprotein (P-gp), the
product of the MDR1 gene, are linked to resistance in
chemotherapy (Widmer et al., 2003). It was demonstrated
that treatment of doxorubicin-resistant K562 cells with
1 µM imatinib in combination with the p-glycoprotein
inhibitor verapamil significantly suppressed cell growth
(Mahon et al., 2003). In addition, the ABCA subfamily
genes (ABCA2, ABCA3, ABCA6) also have a role in the
drug resistance mechanism (Dean et al., 2001; Vasiliou
et al., 2009). It was found that expression of the ABCA3
transporter gene and drug resistance are correlated. After
the expression level of the ABCA3 gene was decreased with
specific small interfering RNA (siRNA), imatinib activity
was increased in K562 and LAMA 84 CML cells (Chapuy
et al., 2009).
2.4. Organic cation transporters (hOCT1)
Human organic cation transporter (hOCT1) controls
the uptake of substances through the cell membrane.
Imatinib is one of the substrates of hOCT1 and is affected
by expression levels of this transmembrane protein.
Decreasing hOCT1 levels cause a low intracellular
concentration of imatinib in the cytoplasm, and therefore
the therapeutic activity of the drug is weakened in the
cell (Wang et al., 2008). As a second-line treatment agent,
nilotinib is administered to imatinib-resistant patients
with CML. Molecular analyses revealed that transport
of nilotinib is not related to hOCT1 or MDR1 (Davies
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et al., 2009). The high efficacy of nilotinib in MDR1overexpressed patients directs the treatment line in the case
of resistance to imatinib (Agrawal et al., 2013). Another
second-generation TKI, dasatinib, is also effective in terms
of cytogenetic and hematological responses in imatinibresistant patients. A recent study showed that inhibition of
pump activities does not change the inner concentration
of dasatinib despite the fact that it is a substrate of MDR1
and ABCG2 transporters (Hiwase et al., 2013).
2.5. Aberrant ceramide metabolism
Sphingolipids are bioactive metabolites that have
essential roles in cellular functions such as cell cycle
regulation, proliferation, metabolism, and drug resistance.
Sphingolipid metabolism contains ceramide, sphingosine,
glycosylceramide (GC), ceramide-1-phosphate (C1P),
sphingomyelin (SM), and sphingosine-1-phosphate (S1P)
(Hannun and Obeid, 2008).
The backbone of sphingosine metabolism is ceramide.
Metabolism and generation of ceramide determines
the fate of a cell. Conversion of SM to ceramide by
sphingomyelinase is generally regulated by stress
conditions (Gilbert et al., 2006; Figure 2).
Stimulation of ceramide production is mediated by
Fas/CD95 triggered cell death (Lin et al., 2000). Moreover,
sphingosine is synthesized from ceramide by ceramidase

enzymes while the reverse reaction occurs via ceramide
synthase. Ceramide is the central molecule of sphingolipid
metabolism mediating programmed cell death (Figure 3).
DNA fragmentation analysis as an indicator of apoptosis
indicates the potency of this sphingolipid derivative on
leukemia cells. This analysis allows determination of
ceramide-related double-stranded DNA degradation
by separation of apoptotic DNA fragments using gel
electrophoresis (Jarvis et al., 1996). Moreover, application
of external ceramides in combination with imatinib (Baran
et al., 2007a), nilotinib (Camgoz et al., 2011), or dasatinib
(Gencer et al., 2011) resulted in synergistic apoptotic
effects of sensitive and drug-resistant CML cells.
In sphingolipid-mediated signaling, whereas ceramide
directly recruits and activates protein kinase-C (PKC),
sphingosine has the potential to inhibit PKC, so low levels
of sphingosine might be responsible for noninhibition
of PKC (Shirahama et al., 1997). S1P, the product of the
sphingosine kinase (SK) enzyme, is another derivative
that is responsible for differentiation, proliferation, and
antiapoptotic regulation (Figure 2). S1P has the reverse
activity of ceramide by preventing cell death triggered by
extrinsic factors. The ceramide/S1P rheostat is a tightly
regulated process with regard to its antagonist effect.
Activation of the oncogenic enzyme SK and increased

Figure 2. De novo synthases and metabolism of ceramide in sphingomyelin pathway. SMS: Sphingomyelin
synthase, S1P: sphingosine-1-phosphate, S1PP: sphingosine-1-phosphate phosphatase, SK: sphingosine
kinase, GCS: glucosylceramide synthase, CRC: cerebrosidase, CS: ceramide synthase, CERK: ceramide
kinase, LPPs: lipid phosphate phosphatases, C1P: ceramide 1 phosphate.
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concentrations of S1P reduce proapoptotic ceramide levels
in the cell (Figure 3). On the other hand, an increasing
level of ceramide diminishes cell survival by inducing
proapoptotic molecules (Bonhoure et al., 2008). It was
shown that inhibition of SK1 by siRNA or application of a
SK1 inhibitor enhanced cell death and increased ceramide
levels in imatinib resistant CML cells (Baran et al.,
2007a, Salas et al., 2011). S1P accumulation prevents the
degradation of Bcr-abl1 protein and inhibits programmed
cell death; therefore, the resistance mechanism is triggered
against imatinib (Ekiz and Baran, 2010).
Transfer of a glycose molecule to ceramide by
glycosylceramide synthase (GCS) generates GC, an
important metabolite of bioactive sphingolipids (Figure
2). High GCS activity is a significant factor in cancer
progression and, more importantly, in drug resistance.
This resistance becomes more advanced with the
conversion of proapoptotic ceramide to antiapoptotic
GC (Huang et al., 2011). It was demonstrated that T315
mutant CML cells became more sensitive after treatment
with the GCS inhibitor. Inactivated glycogen synthase
kinase-3 (GSK-3) in Bcr-abl signaling is reactivated by the
GCS inhibitor and initiates apoptotic pathways. Therefore,
the therapeutic potential of GCS inhibitor could be a novel
strategy for drug-resistant patients (Liu et al., 2010). We
also demonstrated that mRNA and protein levels of GCS
are increased in imatinib- and nilotinib-resistant K562
cells (Baran et al., 2011). On the other hand, inhibition of
GCS by application of GCS inhibitor resulted in increased
sensitivity of drug-resistant cells to imatinib (Baran et
al., 2011), nilotinib (Camgoz et al., 2011), and dasatinib
(Gencer et al., 2011) in sensitive and drug-resistant cells.

2.6. Inhibition of apoptosis
Progression of CML through blast crisis is related to drug
resistance that emerges by the inhibition of apoptosis.
This resistance mechanism is accompanied by different
genes or proteins that have a role in apoptotic signaling
pathways. On the other hand, several polypeptides are
selectively degraded by proteases. The precursor proteases,
caspases, direct the apoptotic process in the cell. The Bcl2 antiapoptotic protein family contributes to the intrinsic
pathway while the inhibitor of apoptosis (IAP) protein
family has a role in regulation of downstream apoptotic
processes. Survival mechanisms of CML cells require
the coordination of proteins to modulate apoptosis
(Rumjanek et al., 2013). The Tp53 tumor suppressor gene
encodes the p53 protein and has several functions such as
cell cycle regulation, DNA repair, programmed cell death,
and genomic stability, making p53 one of the essential
molecules in the cell (Naccarati et al., 2012). It was shown
that CML progression is related to p53 mutation. CML
patients whose exon 8 region of the Tp53 gene is mutated
have higher accelerated phase and blast crisis values. In
addition, the molecular response is decreased during
treatment with imatinib, thus increasing the influence of
the mutation on CML (Mir et al., 2013). Stabilization of
p53 also triggers apoptosis in CML.
Mitochondria-dependent cell death is mediated by
the Bcl-2 protein family. The intrinsic apoptotic pathway
is triggered by antiapoptotic Bcl-2 and proapoptotic Bax,
Bim, and Bid-like proteins, which regulate cytochrome-c
release. Overexpression of Bcl-2 encourages aggressive
tumor progression. In an in vitro study it was indicated
that K562 cells treated with imatinib have higher levels of

Figure 3. The balance between sphingolipids determines the cell fate mechanism (cell
survival or cell death).
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Bim. In addition, agents designed against Bcl-xl and Bcl-2
antiapoptotic proteins are a novel therapeutic option for
the treatment of leukemias (Cirinnà et al., 2000; Kuribara
et al., 2004). Extrinsic pathway-dependent apoptosis is
mediated by death receptors. For instance, Fas receptors
include a highly protected DISC domain inducing apoptosis
through activation of caspase cascade. CD95L-stimulated
tumor development supports the idea that apoptosis and
tumor growth might use different pathways (McGahon et
al., 1995; Traer et al., 2012; Rumjanek et al., 2013). IAP is
associated with the inhibition of programmed cell death.
IAP and XIAP (another inhibitor protein) are highly
expressed in CML cells and have a strong association with
Pgp/ABCB1 (Conte et al., 2005; Silva et al., 2013). Signal
transducer and activator of transcription (STAT) proteins
are cytoplasmic transcription factors that coordinate the
cell proliferation activated by Janus kinase. In leukemia
cells, STAT proteins are activated and enhance the survival
and growth of cells. Therefore, the STAT signaling pathway
is highly potent in therapeutic applications. In our study,
we demonstrated that inhibition of STAT5A through the
use of siRNA increased the apoptotic effects of imatinib
in both sensitive and drug-resistant CML cells (Baran et
al., 2010).
2.7. microRNAs
MicroRNAs (miRNA) are small noncoding RNAs
that play important roles in the transcriptional and
posttranscriptional regulation of gene expression. miRNAs
match the target mRNAs and inhibit their translation.
miRNAs affect many physiological and pathological
processes such as apoptosis, cell proliferation, cell division,
tumorigenesis, and development. Abnormal expression
of miRNAs was observed in hematological malignancies
including chronic myeloid leukemia, chronic lymphocytic
leukemia, multiple myelomas, and B-cell lymphomas.
Some miRNAs act as tumor suppressors and others may

be oncogenic. miRNA levels in the cell are very important
for developing new treatments (Undi et al., 2013).
Different types of miRNAs are also involved in druginduced apoptosis and drug resistance in CML (Table).
For instance, miR-17-19 is downregulated in imatinibtreated CML cells. miR-21 causes the inhibition of cell
migration, cell proliferation, and division, and it also
induces apoptosis. Methylated miR-203 in acute myeloid
leukemia (AML), CML, ALL, and chronic lymphoblastic
leukemia leads to inhibition of Bcr-abl expression. miR451 is important for erythroid homeostasis (Table). ABL1
and Bcr-abl1 are inhibited by miR-29b, and cell growth
and colony formation are also inhibited (Venturini et al.,
2007; Hu et al., 2010; Chim et al., 2011; Çelik et al., 2013).
3. Chronic myeloid leukemia stem cells
There are 2 basic models concerning the origins of cancer.
The clonal origin suggests that tumors can be initiated by
any cells in a population. The other model indicates that
only certain cells in the population [defined as cancer stem
cells (CSC)] can initiate tumor occurrence. Evidence for
CSCs was first presented in leukemias and myelomas. It
was reported that a part of purified leukemic stem cells
separated from hematopoietic stem cells can give rise
to new tumorigenic tissue (Park et al., 1971). The first
characterization of leukemic stem cells was reported by
Bonnet and Dick in AML. When CD34+/CD38– cells
were isolated from AML patients and injected into NOD/
SCID mice, initiation of AML and leukemic blasting in
mice was observed (Bonnet and Dick, 1997).
Major problems encountered during the treatment
process are tumor relapses and drug resistance,
which are thought to originate from CSCs. CSCs are
mainly responsible for tumor initiation, maintenance,
angiogenesis, metastasis, drug resistance, and recurrence

Table. The roles of miRNAs in chronic myeloid leukemia.
ncRNA(s)

ncRNA class

Target

Clinical relevance

miR-7, -23a, -26a, -29a, -29c ,-30b, -30c, -100, -126, -134,
-141, -183, -196b, -199a, -224, -362, -422b, -520a, -191

miRNA

N/A

Predictive response
to therapy

San José-Enériz
et al. 2009

miR-31 downregulation

miRNA

E2F2

Predictive response
to therapy

Rokah et al., 2012

miR-564 downregulation

miRNA

E2F3, Akt2

Predictive response
to therapy

Rokah et al., 2012

miRNA

E2F2, cyclin D1,
K-ras, PIK3R1, SOS1

Predictive response
to therapy

Rokah et al., 2012

miR-155 downregulation

Citation

ncRNA: noncoding RNA, N/A: not available.
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of disease. It was also documented that CD34+ leukemia
stem cells are insensitive to imatinib and dasatinib, and
therefore these applications would be ineffective unless
directly targeting leukemic stem cells to induce apoptosis
(Graham et al., 2002; Hu et al., 2006).
Furthermore, the existence of CSCs is reported in
other solid tumors. Breast cancer is the first solid tumor
in which CSCs with the CD44+/CD24– surface marker
was identified (Al-Hajj et al., 2003). Many CSCs have been
identified and characterized for brain tumors, lung cancer,
colon cancer, pancreas cancer, and prostate cancer so far
(Singh et al., 2003; Kim et al., 2005; Ricci-Vitiani et al.,
2007; Li et al., 2009; Goldstein et al., 2010).
Signaling pathways such as BMI-1, Notch, and
Hedgehog have important roles in stemness and also
regulate the activities of CSCs. After developing mice
deficient in β-catenin in the hematopoietic cells, HSC
and CSCs were isolated. Results showed a lack of the
capacity for self-renewal, indicating the requirement of
Wnt signaling in CSC maintenance (Zhao et al., 2007).
The Hedgehog signaling pathway is as important as the
Wnt signaling pathway in terms of stem cell regulation
and embryonic formation. Suppression of Smoothened
(Smo) decreased the triggering of CML stem cells in
human (Zhao et al., 2009). In addition, it was shown that
there is crosstalk among Sonic Hedgehog, Hox, and Notch
signaling to induce the potential of CSCs (Sengupta et al.,
2007).
Since potential drugs target cancer cells instead of
CSCs, drug resistance remains the major problem during
treatment. In order to prevent the production of new
cancer cells by cancer stem cells and to overcome reversal
of resistance, recent studies have focused on targeting
CSCs. It was agreed that imatinib and other TKIs could
not be effective on cancer stem cells due to disease relapse
in the long-term (Corbin et al., 2011; Perl and Carroll,
2011). Distinguishing cancer stem cells from normal stem
cells is another crucial point for the success of treatment.
It is possible to eliminate normal stem cells by targeting
the B-lymphoid kinase gene (Blk), which acts as a tumor
suppressor in leukemic stem cells. However, this gene
does not show any activity in normal hematopoietic stem
cells. Decreased levels of Blk resulted in high potency
of leukemic stem cells, while high levels of Blk caused
inhibition of CSCs. Suppression of Blk by targeting its
upstream regulator Pax5 or downstream effector p27
could be a possible target for elimination of CSCs (Zhang
et al., 2012). Jak2/STAT5 is another potential target for
CSCs and is related to drug resistance and CSC activity
in leukemia cells (Jørgensen and Holyoake, 2007; Samanta
et al., 2011). Compared to normal stem cells, SIRT1
(NAD+ dependent deacetylase), an inactivator of p53, is
overexpressed in leukemic stem cells. It was reported that
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SIRT1 knockdown combined with imatinib triggered p53
activation and apoptosis synergistically in CML stem cells
(Li et al., 2012). It was also shown that imatinib treatment
increased the survival rate in SIRT1 gene knockout mice.
Therefore, SIRT1 could be a novel target for reversal of
drug resistance in CML (Yuan et al., 2012).
4. Reversal of resistance
Drug resistance is the major problem of the clinical
process, causing disease reoccurrence and tumor relapse.
In recent years, there have been increasing studies to
overcome the problem of drug resistance. Researchers have
focused on the reversal of resistance and many techniques
have been developed. There are various methods such
as signaling pathway targeting, direct protein targeting,
nanotechnology, or knockdown/knockout techniques.
TKIs and their effects on MDR were shown as potential
agents for reversal of drug resistance. The combination
of imatinib and 5-bromotetrandrine has a significant
reversal effect on the K562/A02 cell line by decreasing
the MDR1 gene and downregulating P-gp expression
while increasing apoptosis (Chen et al., 2010). It was also
indicated that nilotinib reverses resistance by blocking
ABCB1 and ABCG2 transporters (Tiwari et al., 2009). On
the other hand, salinomycin was found to be an effective
agent to overcome ABC transporter-mediated drug
resistance and apoptosis resistance in leukemic stem cells
(Fuchs et al., 2010; Riccioni et al., 2010). In vivo studies
have also demonstrated that imatinib combined with
vincristine significantly suppresses tumor initiation in
multidrug-resistant CML cells in a human-nude mouse
xenograft model (Gao et al., 2006). In another study,
imatinib was a highly effective agent for P-glycoproteinmediated resistance, whereas, in imatinib-resistant cell
lines, cepharanthine was reported as able to overcome the
resistance of K562/MDR cells (Mukai et al., 2003).
The Hedgehog signaling pathway prominent during
cell proliferation was affected by suppression of the
B4GALT1, gene which resulted in overcoming multidrug
resistance in human K562 adriamycin-resistant cells
(Zhou et al., 2012). The phosphatidylinositol-3-kinase/
protein kinase B (PI3-K/Akt) signaling pathway is one
of the important signaling pathways for cell survival. In
human leukemia cells, LY294002, an inhibitor of PI3-K,
reverses P-glycoprotein-mediated resistance (Zhang et al.,
2009). Human K562 leukemic cells are resistant to tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)
mediated apoptosis. It was shown that it is possible to
reverse resistance by knocking down the DNA-PKCs/Akt
pathway activated by TRAIL-induced apoptosis (Kim et
al., 2009).
Nanotechnology has become an important tool for
cancer treatment and reversal of resistance. Many studies
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in this area have used nanoparticles. For example, as a system
for targeted drug delivery, magnetic nanoparticles were
used with wogonin and Fe3O4 for the reversal of MDR by
downregulating MDR1 in K562 cells (Cheng et al., 2012). It
was also indicated that the combination of daunorubicin and
5-bromotetrandrine or imatinib and 5-bromotetrandrine
loaded onto iron oxide nanoparticles could overcome MDR
(Chen et al., 2010; Cheng et al., 2011). Furthermore, magnetic
nanoparticles with daunorubicin increased apoptosis and
reversed MDR in K562-n/VCR cell vaccinated nude mice in
in vivo studies (Chen et al., 2009). Targeting CSC-specific
miRNAs with curcumin or epigallocatechin-3-gallate was
reported as a potential technique for reversal of resistance
(Wang et al., 2010).

5. Conclusion and future perspectives
Leukemia is a heavily investigated type of cancer for the
development of new therapy strategies to cure the disease
or increase patient quality of life. Although patients may
respond to chemotherapy in the short term, after treatment,
relapse can be observed. Rather than the development of
new agents, it is better to focus on drug resistance and its
mechanisms. A better understanding of the mechanisms
of drug resistance could open new research areas and take
us one step forward in cancer treatment.
Acknowledgment
We would like to thank Prof Dr Anne Frary for English
editing of the article.

References
Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Saussele S, Fabarius
A, Purkayasatha D, Woodman RC, Hehlmann R et al (2013).
MDR1 gene expression predicts response and progression-free
survival Of Ph+ CML patients on second-line nilotinib therapy
after imatinib failure - 4-year follow-up. Blood 122: 1494.
Al-Achkar W, Wafa A, Moassass F, Othman MAK (2012). A novel
dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL
rearrangement in an Imatinib resistant chronic myeloid
leukemia. Mol Cytogenet 5: 36.

Bonnet D, Dick JE (1997). Human acute myeloid leukemia is
organized as a hierarchy that originates from a primitive
hematopoietic cell. Nat Med 3: 730–737.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker
BJ, Lydon NB (1996). Inhibition of the Abl protein-tyrosine
kinase in vitro and in vivo by a 2-phenylaminopyrimidine
derivative. Cancer Res 56: 100–104.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF
(2003). Prospective identification of tumorigenic breast cancer
cells. P Natl Acad Sci USA 100: 3983–3988.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass
U, Lydon NB (1995). Selective inhibition of the platelet-derived
growth factor signal transduction pathway by a proteintyrosine kinase inhibitor of the 2-phenylaminopyrimidine
class. P Natl Acad Sci USA 92: 2558–2562.

An X, Tiwari AK, Sun Y, Ding P, Ashby CR, Chen Z (2010). BCRABL tyrosine kinase inhibitors in the treatment of Philadelphia
chromosome positive chronic myeloid leukemia: a review.
Leukemia Res 34: 1255–1268.

Calderón-Cabrera C, Montero I, Morales RM, Sánchez J, Carrillo
E (2013). Differential cytogenetic profile in advanced
chronic myeloid leukemia with sequential lymphoblastic and
myeloblastic blast crisis. Leukemia Res Rep 2: 79–81.

Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G (2014).
Treatment recommendations for chronic myeloid leukemia.
Mediterr J Hematol Infect Dis 6: e2014005.

Camgoz A, Gencer EB, Ural AU, Baran Y (2013). Mechanisms
responsible for nilotinib resistance in human chronic myeloid
leukemia cells and reversal of resistance. Leuk Lymp 54: 1279–
1287.

Baran Y, Bielawski J, Gunduz U, Ogretmen B (2011). Targeting
glucosylceramide synthase sensitizes imatinib-resistant
chronic myeloid leukemia cells via endogenous ceramide
accumulation. J Cancer Res Clin Oncol 137: 1535–1544.
Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM,
Ogretmen B (2007a). Alterations of ceramide/sphingosine
1-phosphate rheostat involved in the regulation of resistance to
imatinib-induced apoptosis in K562 human chronic myeloid
leukemia cells. J Biol Chem 282: 10922–10934.
Baran Y, Ural AU, Gunduz U (2007b). Mechanisms of cellular
resistance to imatinib in human chronic myeloid leukemia
cells. Hematology 12: 497–503.
Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama
T, Melo JV, Cuvillier O (2008). Sphingosine kinase-1 is a
downstream regulator of imatinib-induced apoptosis in
chronic myeloid leukemia cells. Leukemia 22: 971–979.

Camgoz A, Ural AU, Avcu F, Baran Y (2011). Targeting ceramide
metabolism to increase intracellular concentrations of
apoptotic ceramide increased cytotoxic effects of nilotinib in
human chronic myeloid leukemia cells. Leuk Lymp 52: 1574–
1584.
Çelik DA, Koşar PA, Özçelik N (2013). MikroRNA’lar ve kanser ile
ilişkisi. SDÜ Tıp Fakültesi Dergisi 20: 121–127 (in Turkish).
Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles
R, Lawler SD, Groffen J, Foulkes JG, Greaves MF et al (1987).
A novel abl protein expressed in Philadelphia chromosome
positive acute lymphoblastic leukaemia. Nature 325: 635–637.
Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N,
Haase D, Truemper L, Wulf GG (2009). ABC transporter A3
facilitates lysosomal sequestration of imatinib and modulates
susceptibility of chronic myeloid leukemia cell lines to this
drug. Haematologica 94: 1528–1536.

813

ÜNLÜ et al. / Turk J Biol
Chen BA, Lai BB, Cheng J, Xia GH, Gao F, Xu WL, Ding JH, Gao C,
Sun XC, Xu CR et al (2009). Daunorubicin-loaded magnetic
nanoparticles of Fe3O4 overcome multidrug resistance
and induce apoptosis of K562-n/VCR cells in vivo. Int J
Nanomedicine 4: 201–208.
Chen BA, Shan XY, Chen J, Xia GH, Xu WL, Schmit M (2010).
Effects of imatinib and 5-bromotetrandrine on the reversal of
multidrug resistance of the K562/A02 cell line. Chin J Cancer
29: 591–595.
Cheng J, Cheng L, Chen B, Xia G, Gao C, Song H, Bao W, Guo Q,
Zhang H, Wang X (2012). Effect of magnetic nanoparticles of
Fe3O4 and wogonin on the reversal of multidrug resistance in
K562/A02 cell line. Int J Nanomed 7: 2843–2852.
Cheng J, Wang J, Chen B, Xia G, Cai X, Liu R, Ren Y, Bao W, Wang
X (2011). A promising strategy for overcoming MDR in
tumor by magnetic iron oxide nanoparticles co-loaded with
daunorubicin and 5-bromotetrandrin. Int J Nanomed 6: 2123–
2131.
Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu
L (2011). Epigenetic inactivation of the hsa-miR-203 in
haematological malignancies. J Cell Mol Med 15: 2760–2767.
Cirinnà M, Trotta R, Salomoni P, Kossev P, Wasik M, Perrotti D,
Calabretta B (2000). Bcl-2 expression restores the leukemogenic
potential of a BCR/ABL mutant defective in transformation.
Blood 96: 3915–3921.
Comert M, Baran Y, Saydam G (2013). Changes in molecular biology
of chronic myeloid leukemia in tyrosine kinase inhibitor era.
Am J Blood Res 3: 191–200.
Conte E, Stagno F, Guglielmo P, Scuto A, Consoli C, Messina A
(2005). Survivin expression in chronic myeloid leukemia.
Cancer Lett 225: 105–110.
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker
BJ (2011). Human chronic myeloid leukemia stem cells are
insensitive to imatinib despite inhibition of BCR-ABL activity.
J Clin Invest 121: 396–409.
Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I,
Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis
AM et al (2012). Bosutinib versus imatinib in newly diagnosed
chronic-phase chronic myeloid leukemia: results from the
BELA trial. J Clin Oncol 30: 3486–3492.
Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia
S, Harris RJ, Jørgensen HG, Holyoake TL, Pirmohamed M,
Clark RE et al (2009). Nilotinib concentration in cell lines
and primary CD34+ chronic myeloid leukemia cells is not
mediated by active uptake or efflux by major drug transporters.
Leukemia 23: 1999–2006.
Dean M, Rzhetsky A, Allikmets R (2001). The human ATP-binding
cassette (ABC) transporter superfamily. Genome Res 11:
1156–1166.
Deininger MW, Goldman JM, Melo JV (2000). The molecular biology
of chronic myeloid leukemia. Blood 96: 3343–3356.
Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G,
Verweij J, Loos WJ, Wiemer EA, Mathijssen RH (2011). Drug
transporters and imatinib treatment: implications for clinical
practice. Clin Cancer Res 17: 406–415.

814

Ekiz HA, Baran Y (2010). Therapeutic applications of bioactive
sphingolipids in hematological malignancies. Int J Cancer 127:
1497–1506.
Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H
(2014). Association of MDR1 gene polymorphism (G2677T)
with imatinib response in Egyptian chronic myeloid leukemia
patients. Hematology 19: 123–128.
Fausel C (2007). Targeted chronic myeloid leukemia therapy: seeking
a cure. Am J Health Syst Pharm 64: 9–15.
Frazer R, Irvine AE, McMullin MF (2007). Chronic myeloid
leukaemia in the 21st century. Ulster Med J 76: 8–17.
Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat G (2010).
Salinomycin overcomes ABC transporter-mediated multidrug
and apoptosis resistance in human leukemia stem cell-like KG1a cells. Biochem Biophys Res Commun 394: 1098–1104.
Gao L, Chen L, Fei XH, Qiu HY, Zhou H, Wang JM (2006). STI571
combined with vincristine greatly suppressed the tumor
formation of multidrug-resistant K562 cells in a human-nude
mice xenograft model. Chin Med J (Engl) 119: 911–918.
Gencer EB, Ural AU, Avcu F, Baran Y (2011). A novel mechanism
of dasatinib-induced apoptosis in chronic myeloid leukemia;
ceramide synthase and ceramide clearance genes. Ann Hemat
90: 1265–1275.
Gilbert SJ, Blain EJ, Jones P, Duance VC, Mason DJ (2006).
Exogenous sphingomyelinase increases collagen and
sulphated glycosaminoglycan production by primary articular
chondrocytes: an in vitro study. Arthritis Res Ther 8: R89.
Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010).
Identification of a cell of origin for human prostate cancer.
Science 329: 568–571.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao
PN, Sawyers CL (2001). Clinical resistance to STI-571 cancer
therapy caused by BCR-ABL gene mutation or amplification.
Science 293: 876–880.
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ,
Richmond L, Holyoake TL (2002). Primitive, quiescent,
Philadelphia-positive stem cells from patients with chronic
myeloid leukemia are insensitive to STI571 in vitro. Blood 99:
319–325.
Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R (2013).
Emerging therapeutic strategies for targeting chronic myeloid
leukemia stem cell. Stem Cell Int 2013: 724360.
Hannun YA, Obeid LM (2008). Principles of bioactive lipid signalling:
lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139–150.
Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL,
Hughes TP (2013). Dasatinib targets chronic myeloid
leukemia-CD34+ progenitors as effectively as it targets mature
cells. Haematologica 98: 896–900.
Hu H, Li Y, Gu J, Zhu X, Dong D, Yao J, Lin C, Fei J (2010). Antisense
oligonucleotide against miR- 21 inhibits migration and induces
apoptosis in leukemic K562 cells. Leukemia Lymphoma 51:
694–701.

ÜNLÜ et al. / Turk J Biol
Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S (2006).
Targeting multiple kinase pathways in leukemic progenitors
and stem cells is essential for improved treatment of Ph+
leukemia in mice. P Natl Acad Sci USA 103: 16870–16875.

Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen
W, Bhatia R (2012). Activation of p53 by SIRT1 inhibition
enhances elimination of CML leukemia stem cells in
combination with imatinib. Cancer Cell 21: 266–281.

Huang WC, Tsai CC, Chen CL, Chen TY, Chen YP, Lin YS, Lu
PJ, Lin CM, Wang SH, Tsao CW (2011). Glucosylceramide
synthesis inhibitor PDMP sensitizes chronic myeloid leukemia
T315I mutant to Bcr-abl inhibitor and cooperatively induces
glycogen synthase kinase-3-regulated apoptosis. FASEB J 25:
3661–3673.

Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, Paris
F, Fuks Z, Schuchman EH, Kolesnick RN et al (2000). Role of
acidic sphingomyelinase in Fas/CD95-mediated cell death. J
Biol Chem 275: 8657–8663.

Huang X, Cortes J, Kantarjian H (2012). Estimations of the increasing
prevalence and plateau prevalence of chronic myeloid leukemia
in the era of tyrosine kinase inhibitor therapy. Cancer 118:
3123–3127.
Jabbour E, Lipton JH (2013). A critical review of trials of first-line
BCR-ABL inhibitor treatment in patients with newly diagnosed
chronic myeloid leukemia in chronic phase. Clin Lymphoma
Myeloma Leuk 13: 646–656.
Jabbour EJ, Cortes JE, Kantarjian HM (2013). Resistance to tyrosine
kinase inhibition therapy for chronic myelogenous leukemia:
a clinical perspective and emerging treatment options. Clin
Lymphoma Myeloma Leuk 13: 515–529.
Jagani Z, Singh A, Khosravi-Far R (2008). FoxO tumor suppressors
and BCR–ABL-induced leukemia: a matter of evasion of
apoptosis. Biochim Biophys Acta 1785: 63–84.
Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla
RK, Bittman R, Grant S (1996). Induction of apoptosis and
potentiation of ceramide-mediated cytotoxicity by sphingoid
bases in human myeloid leukemia cells. J Biol Chem 271:
8275–8284.
Jørgensen HG, Holyoake TL (2007). Characterization of cancer stem
cells in chronic myeloid leukaemia. Biochem Soc Trans 35:
1347–1351.
Juliano RL, Ling V (1976). A surface glycoprotein modulating drug
permeability in Chinese hamster ovary cell mutants. Biochim
Biophys Acta 455: 152–162.
Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J (2006). New
insights into the pathophysiology of chronic myeloid leukemia
and imatinib resistance. Ann Intern Med 145: 913–923.
Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel
S, Crowley D, Bronson RT, Jacks T (2005). Identification of
bronchioalveolar stem cells in normal lung and lung cancer.
Cell 121: 823–835.
Kim MJ, Kim HB, Bae JH, Lee JW, Park SJ, Kim DW, Park SI, Kang
CD, Kim SH (2009). Sensitization of human K562 leukemic
cells to TRAIL-induced apoptosis by inhibiting the DNAPKcs/Akt-mediated cell survival pathway. Biochem Pharmacol
78: 573–582.
Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K,
Nakazawa S, Hirai H, Ozawa K, Inaba T (2004). Roles of Bim
in apoptosis of normal and Bcr–Abl-expressing hematopoietic
progenitors. Mol Cell Biol 24: 6172–6183.
Li C, Lee CJ, Simeone DM (2009). Identification of human pancreatic
cancer stem cells. Methods Mol Biol 568: 161–173.

Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J,
Mehendale H, Cabot MC, Li YT, Jazwinski SM (2010).
Glucosylceramide synthase upregulates MDR1 expression in
the regulation of cancer drug resistance through cSrc and betacatenin signaling. Mol Cancer 11: 145.
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers
J, Goldman JM, Melo JV (2003). MDR1 gene overexpression
confers resistance to imatinib mesylate in leukemia cell line
models. Blood 101: 2368–2373.
McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG,
Green DR (1995). Regulation of the Fas apoptotic cell death
pathway by Abl. J Biol Chem 270: 22625–22631.
Mir R, Zuberi M, Ahmad I, Javid J, Yadav P, Farooq S, Masroor M,
Guru S, Shanawaz S, Bhat AA (2013). Biological and clinical
implications of exon 8 P53 (R282W) gene mutation in relation
to development and progression of chronic myeloid leukaemia
patients in India population. J Cell Sci Ther 4: 140.
Mukai M, Che XF, Furukawa T, Sumizawa T, Aoki S, Ren XQ,
Haraguchi M, Sugimoto Y, Kobayashi M, Takamatsu H et al
(2003). Reversal of the resistance to STI571 in human chronic
myelogenous leukemia K562 cells. Cancer Sci 94: 557–563.
Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K,
Kumar R, Vodicka P (2012). Mutations and polymorphisms
in TP53 gene--an overview on the role in colorectal cancer.
Mutagenesis 27: 211–218.
Nasr R, Bazarbachi A (2012). Chronic myeloid leukemia: “archetype”
of the impact of targeted therapies. Pathol Biol 60: 239–245
(article in French with English abstract).
Park CH, Bergsagel DE, McCulloch EA (1971). Mouse myeloma
tumor stem cells: a primary cell culture assay. J Natl Cancer
Inst 46: 411–422.
Peng XX, Tiwari AK, Wu HC, Chen ZS (2012). Overexpression of
P-glycoprotein induces acquired resistance to imatinib in
chronic myelogenous leukemia cells. Chin J Cancer 31: 110–
118.
Perl A, Carroll M (2011). BCR-ABL kinase is dead; long live the CML
stem cell. J Clin Invest 121: 22–25.
Press RD, Kamel-Reid S, Ang D (2013). BCR-ABL1 RT-qPCR
for monitoring the molecular response to tyrosine kinase
inhibitors in chronic myeloid leukemia. J Mol Diagn 15: 565–
576.
Quintás-Cardama A, Cortes J (2009). Molecular biology of Bcr-abl1
positive chronic myeloid leukemia. Blood 113: 1619–1630.
Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani
G, Cianfriglia M, Testa U (2010). The cancer stem cell selective
inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells
Mol Dis. 45: 86–92.

815

ÜNLÜ et al. / Turk J Biol
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M,
Peschle C, De Maria R (2007). Identification and expansion of
human colon-cancer-initiating cells. Nature 445: 111–115.
Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M,
Toren A, Shomoron N, Shpilberg O (2012). Downregulation
of Mir-31, Mir-155, and Mir-564 in chronic myeloid leukemia
cells. PLoS One 7: e35501.
Rumjanek VM, Vidal RS, Maia RC (2013). Multidrug resistance
in chronic myeloid leukaemia: how much can we learn from
MDR-CML cell lines? Biosci Rep 25: 33.
Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP,
Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR
(2011). Sphingosine kinase-1 and sphingosine 1-phosphate
receptor 2 mediate Bcr-abl1 stability and drug resistance by
modulation of protein phosphatase 2A. Blood 117: 5941–5952.
Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R,
Priebe W, Arlinghaus R (2011). Janus kinase 2 regulates Bcr-abl
signaling in chronic myeloid leukemia. Leukemia 25: 463–472.
San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L,
Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P,
Calasanz MJ, Prósper F et al. (2009). MicroRNA expression
profiling in imatinib-resistant chronic myeloid leukemia
patients without clinically significant ABL1-mutations. Mol
Cancer 2009 8: 69.
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB,
Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW
et al (2002). Imatinib induces hematologic and cytogenetic
responses in patients with chronic myelogenous leukemia
in myeloid blast crisis: results of a phase II study. Blood 99:
3530–3539.
Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R,
Banerjee S (2007). Deregulation and cross talk among Sonic
hedgehog, Wnt, Hox and Notch signaling in chronic myeloid
leukemia progression. Leukemia 21: 949–955.
Shirahama T, Sweeney EA, Sakakura C, Singhal AK, Nishiyama
K, Akiyama S, Hakomori S, Igarashi Y (1997). In vitro
and in vivo induction of apoptosis by sphingosine and N,
N-dimethylsphingosine in human epidermoid carcinoma
KB-3-1 and its multidrug-resistant cells. Clin Cancer Res 3:
257–264.
Silva KL, de Souza PS, de Moraes GN, Moellmann-Coelho
A, da Cunha Vasconcelos F, Maia RC (2013). XIAP and
P-glycoprotein co-expression is related to imatinib resistance
in chronic myeloid leukemia cells. Leuk Res 37: 1350–1358.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J,
Dirks PB (2003). Identification of a cancer stem cell in human
brain tumors. Cancer Res 63: 5821–5828.
Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen
X, Chen ZS (2009). Nilotinib (AMN107, Tasigna) reverses
multidrug resistance by inhibiting the activity of the ABCB1/
Pgp and ABCG2/BCRP/MXR transporters. Biochem
Pharmacol 78: 153–161.

816

Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O’Hare T,
Druker BJ, Deininger MW (2012). Blockade of JAK2-mediated
extrinsic survival signals restores sensitivity of CML cells to
ABL inhibitors. Leukemia 26: 1140–1143.
Undi RB, Kandi R, Gutti RK (2013). MicroRNAs as haematopoiesis
regulators. Adv Hematol 2013: 695754.
Vasiliou V, Vasiliou K, Nebert DW (2009). Human ATP-binding
cassette (ABC) transporter family. Hum Genomics 3: 281–290.
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A,
Muckenthaler MU, Ganser A, Scherr M (2007). Expression
of the miR-17-92 polycistron in chronic myeloid leukemia
(CML) CD34+ cells. Blood 109: 4399–4405.
Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M,
Clark RE (2008). Expression of the uptake drug transporter
hOCT1 is an important clinical determinant of the response to
imatinib in chronic myeloid leukemia. Clin Pharmacol Therap
83: 258–264.
Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH
(2010). Targeting miRNAs involved in cancer stem cell and
EMT regulation: an emerging concept in overcoming drug
resistance. Drug Resist Updat 13: 109–118.
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin
JD (2007). Second generation inhibitors of BCR-ABL for the
treatment of imatinib-resistant chronic myeloid leukaemia.
Nature Reviews Cancer 7: 345–356.
Widmer N, Colombo S, Buclin T, Decosterd LA (2003). Functional
consequence of MDR1 expression on imatinib intracellular
concentrations. Blood 102: 1142.
Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen
WY (2012). Activation of stress response gene SIRT1 by BCRABL promotes leukemogenesis. Blood 119: 1904–1914.
Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny
J, Hutchinson L, Higgins A et al (2012). The Blk pathway
functions as a tumor suppressor in chronic myeloid leukemia
stem cells. Nat Genet 44: 861–871.
Zhang Y, Qu XJ, Liu YP, Yang XH, Hou KZ, Teng YE, Zhang JD (2009).
Reversal effect of PI3-K inhibitor LY294002 on P-glycoproteinmediated multidrug resistance of human leukemia cell line
K562/DNR and gastric cancer cell line SGC7901/ADR. Ai
Zheng 28: 97–99.
Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A,
Reya T (2007). Loss of beta-catenin impairs the renewal of
normal and CML stem cells in vivo. Cancer Cell 12: 528–541.
Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum
J, Kwon HY, Kim J, Chute JP, Rizzieri D et al (2009). Hedgehog
signalling is essential for maintenance of cancer stem cells in
myeloid leukaemia. Nature 458: 776–779.
Zhou H, Zhang Z, Liu C, Jin C, Zhang J, Miao X, Jia L (2012).
B4GALT1 gene knockdown inhibits the hedgehog pathway
and reverses multidrug resistance in the human leukemia
K562/adriamycin-resistant cell line. IUBMB Life 64: 889–900.

